Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02874274 · ClinicalTrials.gov registry record · NA

Vaccination Uptake (VAX) in PD

A NA study, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
164
Enrollment target

NCT02874274: Completed NA study, sponsored by NYU Langone Health.

NCT02874274 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 164 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02874274, a NA study, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
164 participants
Enrollment target

Study Summary

This is a study to see whether participation in the Edmond J. Safra Interdisciplinary Home Visit Program for Advanced Parkinson's (HVP) increases the rate of age-appropriate vaccinations in people with advanced Parkinson's Disease (PD) and related disorders. This study will evaluate the impact of the HVP on the rate of common illnesses such as flu and pneumonia in patients with advanced PD and related disorders over the course of one year. As there is currently no data available on the baseline rate of vaccinations in either homebound or less disabled PD populations, investigators will seek to establish the baseline rate of vaccinations, barriers to getting vaccinated, and baseline healthcare utilization in these populations by piloting (Phase 1) and then implementing (Phase 2) a survey via telephone interviews. Investigators will then test feasibility of offering influenza and pneumococcal vaccinations, as appropriate, to the homebound individuals in our HVP cohort (Phase 3), and will compare their pre- and post-intervention rates of both outpatient and acute healthcare utilization and self-reported illness.

Primary Outcome

A rating scale used to follow the longitudinal course of Parkinson's disease

Interventions

  • BEHAVIORAL Standard of Care
  • BEHAVIORAL Home Visit Program (HVP)

Trial Details

FieldValue
Enrollment Target 164 participants
Start Date 2016-09
Est. Completion 2018-04-12
Phase NA
NYU Langone Health

1,164 total trials

What the finished NCT02874274 record still lists

NCT02874274 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).

The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.

NCT02874274 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02874274 about?

NCT02874274 is a clinical study titled "Vaccination Uptake (VAX) in PD". This is a study to see whether participation in the Edmond J. Safra Interdisciplinary Home Visit Program for Advanced Parkinson's (HVP) increases the rate of age-appropriate vaccinations in people with advanced Parkinson's Disease (PD) and related disorders. This study will evaluate the impact of th...

What is the current status of trial NCT02874274?

This trial is currently completed. It is a NA study. The enrollment target is 164 participants. The study started on 2016-09. Estimated completion is 2018-04-12.

What interventions are being tested in trial NCT02874274?

The interventions under investigation include: Standard of Care (BEHAVIORAL), Home Visit Program (HVP) (BEHAVIORAL).

Who is sponsoring clinical trial NCT02874274?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02874274's enrollment target sits among peer trials

164 626th of 2000 higher than 1,374 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04891289 · 164 participants · Phase 2

    Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

  • NCT04893226 · 164 participants · NA

    Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women

  • NCT05270213 · 164 participants · Phase 1

    Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

  • NCT05543681 · 164 participants · Phase 2

    Clinical Trial on Agitation in Alzheimer's Dementia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02874274, the US trial registry maintained by the National Library of Medicine. NCT02874274 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.